Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Refinement of computational identification of somatic copy number alterations using DNA methylation microarrays illustrated in cancers of unknown primary

  • Blecua, Pedro|||0000-0002-1012-0300
  • Davalos, Veronica|||0000-0003-4077-5137
  • De Villasante, Izar|||0000-0001-7325-0631
  • Merkel, Angelika|||0000-0001-5164-6803
  • Musulén, Eva|||0000-0002-9667-6464
  • Coll-Sanmartin, Laia
  • Esteller, M|||0000-0003-4490-6093
High-throughput genomic technologies are increasingly used in personalized cancer medicine. However, computational tools to maximize the use of scarce tissues combining distinct molecular layers are needed. Here we present a refined strategy, based on the R-package 'conumee', to better predict somatic copy number alterations (SCNA) from deoxyribonucleic acid (DNA) methylation arrays. Our approach, termed hereafter as 'conumee-KCN', improves SCNA prediction by incorporating tumor purity and dynamic thresholding. We trained our algorithm using paired DNA methylation and SNP Array 6.0 data from The Cancer Genome Atlas samples and confirmed its performance in cancer cell lines. Most importantly, the application of our approach in cancers of unknown primary identified amplified potentially actionable targets that were experimentally validated by Fluorescence in situ hybridization and immunostaining, reaching 100% specificity and 93.3% sensitivity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validation of a DNA methylation microarray for 285,000 CpG sites in the mouse genome

  • García-Prieto, Carlos A|||0000-0001-5021-6916
  • Álvarez-Errico, Damiana|||0000-0002-7921-5164
  • Musulén, Eva|||0000-0002-9667-6464
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Vazquez Prat, Berta Nieves|||0000-0002-8164-3926
  • Vaquero, Alejandro|||0000-0002-8735-4156
  • Esteller, M|||0000-0003-4490-6093
Mouse has been extensively used as a model organism in many studies to characterize biological pathways and drug effects and to mimic human diseases. Similar DNA sequences between both species facilitate these types of experiments. However, much less is known about the mouse epigenome, particularly for DNA methylation. Progress in delivering mouse DNA methylomes has been slow due to the currently available time-consuming and expensive methodologies. Following the great acceptance of the human DNA methylation microarrays, we have herein validated a newly developed DNA methylation microarray (Infinium Mouse Methylation BeadChip) that interrogates 280,754 unique CpG sites within the mouse genome. The CpGs included in the platform cover CpG Islands, shores, shelves and open sea sequences, and loci surrounding transcription start sites and gene bodies. From a functional standpoint, mouse ENCODE representative DNase hypersensitivity sites (rDHSs) and candidate cis-Regulatory Elements (cCREs) are also included. Herein, we show that the profiled mouse DNA methylation microarray provides reliable values among technical replicates; matched results from fresh frozen versus formalin-fixed samples; detects hemimethylated X-chromosome and imprinted CpG sites; and is able to determine CpG methylation changes in mouse cell lines treated with a DNA demethylating agent or upon genetic disruption of a DNA methyltransferase. Most important, using unsupervised hierarchical clustering and t-SNE approaches, the platform is able to classify all types of normal mouse tissues and organs. These data underscore the great features of the assessed microarray to obtain comprehensive DNA methylation profiles of the mouse genome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies

  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Villanueva, Lorea|||0000-0003-1858-7076
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Davalos, Veronica|||0000-0003-4077-5137
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Juan, Manel|||0000-0002-3064-1648
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Delgado, Julia
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Del Bufalo, Francesca
  • Locatelli, Franco|||0000-0002-7976-3654
  • Quintarelli, Concetta
  • Sinibaldi, Matilde
  • Soler, Marta|||0000-0002-6656-957X
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Urdinguio, Rocío G.|||0000-0003-2736-5758
  • Fernandez, Agustin F.
  • Fraga, Mario|||0000-0001-8450-2603
  • Bar, Diana
  • Meir, Agustín
  • Itzhaki, Orit
  • Besser, MichalJ.
  • Avigdor, Abraham
  • Jacoby, Elad
  • Esteller, M.|||0000-0003-4490-6093
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. The increasingly recognized relevance of epigenetic changes in cancer immunology prompted us to determine the impact of the DNA methylation profiles of CART19 cells on the clinical course. Methods: We recruited 114 patients with B-cell malignancies, comprising 77 patients with acute lymphoblastic leukemia and 37 patients with non-Hodgkin lymphoma who were treated with CART19 cells. Using a comprehensive DNA methylation microarray, we determined the epigenomic changes that occur in the patient T cells upon transduction of the CAR vector. The effects of the identified DNA methylation sites on clinical response, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, event-free survival, and overall survival were assessed. All statistical tests were 2-sided. Results: We identified 984 genomic sites with differential DNA methylation between CAR-untransduced and CAR-transduced T cells before infusion into the patient. Eighteen of these distinct epigenetic loci were associated with complete response (CR), adjusting by multiple testing. Using the sites linked to CR, an epigenetic signature, referred to hereafter as the EPICART signature, was established in the initial discovery cohort (n = 79), which was associated with CR (Fisher exact test, P <. 001) and enhanced event-free survival (hazard ratio [HR] = 0.36; 95% confidence interval [CI] = 0.19 to 0.70; P =. 002; log-rank P =. 003) and overall survival (HR = 0.45; 95% CI = 0.20 to 0.99; P =. 047; log-rank P =. 04;). Most important, the EPICART profile maintained its clinical course predictive value in the validation cohort (n = 35), where it was associated with CR (Fisher exact test, P <. 001) and enhanced overall survival (HR = 0.31; 95% CI = 0.11 to 0.84; P =. 02; log-rank P =. 02). Conclusions: We show that the DNA methylation landscape of patient CART19 cells influences the efficacy of the cellular immunotherapy treatment in patients with B-cell malignancy.